BOSTON —
An updated mRNA vaccine demonstrated broad protection against the emerging variant family in final-stage clinical results published this week in a peer-reviewed journal.
The trial enrolled more than 20,000 adults across four continents and reported efficacy above 80 percent against symptomatic disease caused by the new strain lineage.
Trial design
Participants were randomized to receive the updated formulation or a licensed comparator. The primary endpoint was laboratory-confirmed symptomatic infection at least 14 days after the second dose.
Safety profile
The study reported no new safety signals. Injection-site reactions were the most common adverse events, consistent with earlier formulations in the same platform.
The authors stressed that durability remains unknown: follow-up at 12 months is under way.
Public health context
Independent experts called the results reassuring but cautioned that efficacy data from controlled trials do not automatically translate to real-world settings, where prior immunity varies widely.
